Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B21 adjuvant pembrolizumab versus placebo with chemotherapy with or without radiotherapy in high-risk endometrial cancer
MOH_2020-09-24_009355Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) and endometrial carcinosarcoma comparing Pembrolizumab arm with Placebo control arm (2 arms). Started Sep 2020; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on MOH_2020-09-24_009355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-24_009355.